普洛药业(000739.SZ)子公司获得左卡尼汀注射液药品注册证书

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., has received the drug registration certificate for L-carnitine injection from the National Medical Products Administration of China [1] Company Summary - The L-carnitine injection is indicated for patients with chronic renal failure undergoing long-term hemodialysis, addressing complications arising from secondary carnitine deficiency, including cardiomyopathy, skeletal myopathy, arrhythmias, hyperlipidemia, hypotension, and muscle cramps during dialysis [1] - As of the date of the announcement, the total research and development expenses incurred for L-carnitine injection amounted to RMB 3.7629 million [1] Industry Summary - The projected market size for L-carnitine injection in China's hospital market for the year 2024 is estimated to be 103 million doses, with a sales value of RMB 966.5 million [1]